There's no hope of it recovering to its prior heights anytime soon. Moderna's (MRNA -2.63%) stock fell by 13% on Sept. 12 upon the announcement of extensive cost cuts that would affect a handful of its pipeline programs and terminate a few others. Now, management is cautioning investors that a return to routine profitability may not be in the cards for a couple of years. Is the stock's decline just a blip that's part and parcel with the announcement of less-than-great news, or is there a real risk of a long ...